WHO Sets a New Baseline for Childhood Obesity Care
The World Health Organization has issued its first set of guidelines dedicated to obesity in children and adolescents, and the message at its core is unambiguous: for the youngest patients, medicine and surgery are not the answer. Announced on Thursday, the recommendations respond to a steep and sustained climb in obesity rates among young people worldwide, and they draw a clear boundary between how adults and how children should be treated.
Instead of pharmaceutical or surgical intervention, the agency strongly backs structured diets, physical activity and behaviour change as the foundation of care for young people. The guidance arrives as a new generation of appetite-suppressing drugs has reshaped adult obesity treatment, making the decision to exclude children from that approach a deliberate and closely watched one.
No Drugs, Surgery or Weight-Loss Devices for Ages 0–9
The guidelines are explicit about the youngest age band. According to the WHO, pharmacological treatment, bariatric surgery — procedures that alter the stomach or digestive tract — and weight-loss devices should not be used for children aged 0 to 9 years. That position covers the entire span from infancy through early childhood, a period in which the agency sees lifestyle and family-based support as the appropriate route.
For adolescents aged 10 to 19, the doorway to medical treatment opens only narrowly. Approved medicines may be considered in this group solely when a supervised multimodal lifestyle programme has failed to deliver the desired results. Bariatric surgery, meanwhile, may be considered for adolescents with severe obesity, but only under strict conditions.
The distinction matters because it introduces a sequence: support first, and clinical intervention only as a later, conditional step rather than a first response.
A Deliberate Contrast With Adult Guidance
The recommendations for people aged 19 and under sit in sharp contrast to the WHO's adult obesity guidelines, which were published in December 2025 following the surge in popularity of GLP-1 agonists — the appetite-suppressing drug class that includes blockbuster brands such as Ozempic and Mounjaro. For adults, the agency said the range of weight-loss and diabetes medicines could be used to tackle obesity.
The divergence is not accidental. It reflects a different risk calculus for growing bodies, and it places the WHO at odds with any expectation that paediatric care would simply mirror the adult playbook. Where adults may be offered medication as part of a treatment strategy, children under 10 are steered firmly toward behavioural and environmental support, and adolescents face a gated pathway.
The Scale of the Problem: 170 Million Young People
The urgency behind the guidelines is quantifiable. In 2024, roughly 70 million children aged 5 to 9 were living with obesity, alongside 100 million adolescents aged 10 to 19 — about 170 million young people in total, according to WHO figures.
The trend line is steeper still. Among those aged 5 to 19, obesity prevalence rose from 2% in 1990 to 8% in 2024, a fourfold increase over roughly three decades.
- Approximately 70 million children aged 5–9 were obese in 2024.
- Approximately 100 million adolescents aged 10–19 were obese in 2024.
- Prevalence among 5- to 19-year-olds climbed from 2% in 1990 to 8% in 2024.
Luz Maria De Regil, director of the WHO's nutrition and food safety department, described the pattern as global rather than confined to wealthy nations. The rise, she said, is being observed everywhere in all regions, and it is growing in low- and middle-income countries. Some high-income countries, she noted, are beginning to halt the increase — but none has yet managed to bring rates down.
Support, Not Stigma, at the Centre of Care
De Regil framed the guiding principle plainly: the foundation of obesity care for children and adolescents is not medicine or surgery, but access to comprehensive support that enables healthy eating, physical activity and sustainable behaviour change. The emphasis falls on access — the guidelines treat obesity in young people as a condition shaped by circumstances rather than a failure of willpower.
The recommendations also insist that mental health be addressed alongside weight. Anxiety, depression and low self-esteem can feed into unhealthy eating, physical inactivity and social withdrawal, the agency noted, creating loops that are hard to break through diet advice alone. Children and adolescents living with obesity may also face stigma and bullying, experiences that can compound the psychological burden and complicate treatment.
Maria Nieves Garcia Casal, a scientist cited in the WHO material accompanying the guidance, contributed to the body of work behind the recommendations.
What the Guidelines Mean in Practice
Taken together, the recommendations sketch a tiered system of care. For children under 10, the tools are dietary structure, movement and behavioural support, with medication and surgery ruled out. For adolescents, the same foundation applies, but with a defined escalation path when supervised lifestyle programmes fall short and, in cases of severe obesity, a tightly conditioned surgical option.
The framework also implies obligations beyond the clinic. If healthy eating and physical activity are the primary interventions, then families need environments that make both achievable — a point the WHO's emphasis on access and comprehensive support makes clear.
For a generation in which obesity prevalence has quadrupled in relative terms since 1990, the guidelines represent the agency's first formal attempt to set expectations for care. They also stake out a position that will be tested as weight-loss drugs become more widely available and pressure grows to extend their use downward in age. On the WHO's current reading, that boundary holds at 10.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
